Hereditary haemorrhagic telangiectasia: A disease not to be forgotten during the COVID-19 pandemic.
作者信息
Gaetani Eleonora, Passali Giulio Cesare, Riccioni Maria E, Tortora Annalisa, Pola Roberto, Costamagna Guido, Gasbarrini Antonio
机构信息
Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore School of Medicine, Rome, Italy.
Division of Otorhinolaryngology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore School of Medicine, Rome, Italy.
出版信息
J Thromb Haemost. 2020 Jul;18(7):1799-1801. doi: 10.1111/jth.14885.
Abstract
摘要
相似文献
1
Hereditary haemorrhagic telangiectasia: A disease not to be forgotten during the COVID-19 pandemic.遗传性出血性毛细血管扩张症：一种在新冠疫情期间不应被遗忘的疾病。
J Thromb Haemost. 2020 Jul;18(7):1799-1801. doi: 10.1111/jth.14885.
2
Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular disease.2019冠状病毒病大流行期间胸段移植及循环支持的伦理考量：深入探讨肺血管疾病
J Heart Lung Transplant. 2020 Aug;39(8):852-853. doi: 10.1016/j.healun.2020.05.014. Epub 2020 Jun 6.
3
Three further ways that the COVID-19 pandemic will affect health outcomes.新冠疫情将影响健康结果的另外三种方式。
Int J Public Health. 2020 Jun;65(5):519-520. doi: 10.1007/s00038-020-01383-6. Epub 2020 May 5.
4
Informal home care providers: the forgotten health-care workers during the COVID-19 pandemic.非正式家庭护理提供者：新冠疫情期间被遗忘的医护人员。
Lancet. 2020 Jun 27;395(10242):1957-1959. doi: 10.1016/S0140-6736(20)31254-X. Epub 2020 Jun 1.
5
COVID-19, Vascular Diseases, and Vascular Services.2019冠状病毒病、血管疾病与血管服务
Clinics (Sao Paulo). 2020;75:e1979. doi: 10.6061/clinics/2020/e1979. Epub 2020 May 29.
6
Statins and other drugs: Facing COVID-19 as a vascular disease.他汀类药物及其他药物：将新冠病毒病视为一种血管疾病来应对
Pharmacol Res. 2020 Sep;159:105033. doi: 10.1016/j.phrs.2020.105033. Epub 2020 Jun 17.
7
The forgotten fallen: painful reality of a pandemic.被遗忘的逝者：疫情的惨痛现实
Kidney Int. 2020 Aug;98(2):251-252. doi: 10.1016/j.kint.2020.06.002. Epub 2020 Jun 15.
8
Schwartz rounds for healthcare personnel in coping with COVID-19 pandemic.面向医护人员的施瓦茨圆桌会议：应对新冠疫情
Postgrad Med J. 2020 Jul;96(1137):425. doi: 10.1136/postgradmedj-2020-137806. Epub 2020 Apr 28.
9
Covid-19-associated acute haemorrhagic leukoencephalomyelitis.新型冠状病毒肺炎相关急性出血性白质脑脊髓炎
Neurol Sci. 2020 Nov;41(11):3023-3026. doi: 10.1007/s10072-020-04703-z. Epub 2020 Sep 2.
10
Neurological Dysfunction in Coronavirus Disease-19 (COVID-19).新型冠状病毒肺炎（COVID-19）中的神经功能障碍
Acad Radiol. 2020 Sep;27(9):1329-1330. doi: 10.1016/j.acra.2020.05.024. Epub 2020 Jun 10.
引用本文的文献
1
The effect of the COVID-19 pandemic on epistaxis and anaemia in patients with hereditary haemorrhagic telangiectasia (HHT) in central South Africa.新冠疫情对南非中部遗传性出血性毛细血管扩张症（HHT）患者鼻出血和贫血的影响。
Orphanet J Rare Dis. 2025 Jul 16;20(1):364. doi: 10.1186/s13023-025-03777-2.
2
Health outcomes following COVID-19 infection and vaccination in hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症患者感染新冠病毒及接种疫苗后的健康状况
Orphanet J Rare Dis. 2025 Mar 1;20(1):94. doi: 10.1186/s13023-025-03561-2.
3
Impact of SARS-CoV-2 infection in patients with hereditary hemorrhagic telangiectasia: epidemiological and clinical data from the comprehensive Italian retrospective multicenter study.遗传性出血性毛细血管扩张症患者感染 SARS-CoV-2 的影响：来自意大利综合回顾性多中心研究的流行病学和临床数据。
Intern Emerg Med. 2023 Jun;18(4):1109-1118. doi: 10.1007/s11739-023-03287-8. Epub 2023 May 4.
4
A case report on uneventful anticoagulation and persistence of Type 1 Respiratory Failure post severe COVID-19 infection in a patient of Osler-Weber-Rendu syndrome.一例奥斯勒-韦伯-伦杜综合征患者在严重新型冠状病毒肺炎感染后抗凝治疗顺利且1型呼吸衰竭持续存在的病例报告。
J Family Med Prim Care. 2022 Dec;11(12):7941-7945. doi: 10.4103/jfmpc.jfmpc_542_22. Epub 2023 Jan 17.
5
Hereditary Hemorrhagic Telangiectasia Associating Neuropsychiatric Manifestations with a Significant Impact on Disease Management-Case Report and Literature Review.遗传性出血性毛细血管扩张症合并神经精神表现对疾病管理有重大影响——病例报告及文献综述
Life (Basel). 2022 Jul 15;12(7):1059. doi: 10.3390/life12071059.
6
Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy.遗传性出血性毛细血管扩张症患者 COVID-19 的流行病学分布和结局特征：意大利第一波疫情期间的全国性回顾性多中心研究。
Orphanet J Rare Dis. 2021 Sep 8;16(1):378. doi: 10.1186/s13023-021-02000-2.
7
Beneficial Effects of Remote Medical Care for Patients with Hereditary Hemorrhagic Telangiectasia during the COVID-19 Pandemic.新冠疫情期间远程医疗对遗传性出血性毛细血管扩张症患者的有益影响
J Clin Med. 2021 May 25;10(11):2311. doi: 10.3390/jcm10112311.
8
Hereditary hemorrhagic telangiectasia and COVID-19.遗传性出血性毛细血管扩张症与新型冠状病毒肺炎
Rev Soc Bras Med Trop. 2020 Nov 25;53:e20200785. doi: 10.1590/0037-8682-0785-2020. eCollection 2020.
本文引用的文献
1
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会（ISTH）关于新冠病毒病（COVID-19）凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
2
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.新型冠状病毒肺炎与血栓栓塞性疾病：预防、抗栓治疗与随访的相关问题：美国心脏病学会临床实践更新。
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
3
ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment.国际血栓与止血学会（ISTH）关于新型冠状病毒肺炎（COVID-19）凝血功能障碍识别与管理的临时指南：一则评论
J Thromb Haemost. 2020 Aug;18(8):2060-2063. doi: 10.1111/jth.14860. Epub 2020 Jun 14.
4
Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group.遗传性出血性毛细血管扩张症患者抗血栓治疗的安全性：多学科工作组的前瞻性数据。
Orphanet J Rare Dis. 2019 Dec 26;14(1):298. doi: 10.1186/s13023-019-1278-z.
5
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症患者使用直接口服抗凝剂的安全性。
Orphanet J Rare Dis. 2019 Aug 28;14(1):210. doi: 10.1186/s13023-019-1179-1.
6
Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry.静脉血栓栓塞和遗传性出血性毛细血管扩张症患者的自然史。RIETE 登记处的研究结果。
Orphanet J Rare Dis. 2019 Aug 9;14(1):196. doi: 10.1186/s13023-019-1172-8.
7
European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT).欧洲罕见血管疾病参考网络（VASCERN）遗传性出血性毛细血管扩张症（HHT）结局指标。
Orphanet J Rare Dis. 2018 Aug 15;13(1):136. doi: 10.1186/s13023-018-0850-2.
8
Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey.遗传性出血性毛细血管扩张症患者的抑郁和创伤后应激障碍：一项横断面调查。
Thromb Res. 2017 May;153:14-18. doi: 10.1016/j.thromres.2017.03.003. Epub 2017 Mar 9.
9
Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症中表型的循环因素
Front Genet. 2015 Apr 9;6:101. doi: 10.3389/fgene.2015.00101. eCollection 2015.
Zotero 插件